> They have people in their employ that know how to lobby the right regulatory bodies. Theranos had none of this.
No, I think they had plenty of that, look at the makeup of their board. Maybe not exactly from lab testing background, but plenty members with heaps of biotech, pharma, legal and government experience. What they were lacking was a workable product to lobby for. Which I guess is a silver lining to this - that even a $9 billion lobbying effort can't overcome straightup fraud, at least in the biotech sphere. Finance, on the other hand...
No, I think they had plenty of that, look at the makeup of their board. Maybe not exactly from lab testing background, but plenty members with heaps of biotech, pharma, legal and government experience. What they were lacking was a workable product to lobby for. Which I guess is a silver lining to this - that even a $9 billion lobbying effort can't overcome straightup fraud, at least in the biotech sphere. Finance, on the other hand...